The recent FDA approval of the IsoPSA blood test may represent a notable advancement in prostate cancer screening and diagnosis. Developed by Cleveland Diagnostics, the in vitro diagnostic instrument ...
The FDA has granted premarket approval (PMA) to the IsoPSA test, a novel, blood-based in vitro diagnostic kit designed to ...
The FDA has approved a novel diagnostic for prostate cancer that looks to improve upon the common screener for ...
THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...
Mass population testing for prostate cancer will not see men proactively invited for the PSA blood test - here is all you ...
ATLANTA - Each year, millions of American men get a blood test known as a PSA, or prostate-specific antigen, test as part of their yearly checkup. PSA is a protein produced by the prostate gland. If a ...
OXFORD, England--(BUSINESS WIRE)--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch ® 3D genomics platform, today ...
The IsoPSA test is intended to help assess whether patients with elevated PSA levels should go on to receive a biopsy ...
PSA stands for prostate-specific antigen, a substance naturally produced in prostate tissue. A small amount of PSA regularly sneaks into the bloodstream, and low blood concentration is considered ...
MedPage Today on MSN
FDA OKs Blood-Based Test to Help Detect High-Grade Prostate Tumors
The FDA approved Cleveland Diagnostics' blood-based test to help diagnose high-grade prostate tumors and aid in biopsy decisions, the company announced.
Investigators analyzed exfoliated cells in urine specimens to identify 50 candidate RNAs for prostate cancer detection.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback